2020
Psychometric properties of the MATRICS Consensus Cognitive Battery (MCCB) in Chinese patients with major depressive disorder
Liang S, Yu W, Ma X, Luo S, Zhang J, Sun X, Luo X, Zhang Y. Psychometric properties of the MATRICS Consensus Cognitive Battery (MCCB) in Chinese patients with major depressive disorder. Journal Of Affective Disorders 2020, 265: 132-138. PMID: 32090734, DOI: 10.1016/j.jad.2020.01.052.Peer-Reviewed Original ResearchMeSH KeywordsChinaCognitionConsensusDepressive Disorder, MajorHumansNeuropsychological TestsPsychometricsReproducibility of ResultsSchizophrenic PsychologyConceptsMajor depression disorderMATRICS Consensus Cognitive BatteryMDD patientsCognitive impairmentChinese patientsConsensus Cognitive BatteryBipolar disorderHamilton Depression Rating Scale-17Cognitive AssessmentChinese MDD patientsMajor depressive disorderSeverity of symptomsMontreal Cognitive AssessmentConcurrent validityMild cognitive impairmentCognitive batteryPsychometric propertiesGood concurrent validityMedication treatmentDepressive disorderHealthy controlsGood internal consistencyDepressive symptomsDepression disorderPatients
2019
Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia
Tong J, Huang J, Luo X, Chen S, Cui Y, An H, Xiu M, Tan S, Wang Z, Yuan Y, Zhang J, Yang F, Li CR, Hong L, Tan Y. Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia. Brain Behavior And Immunity 2019, 81: 213-219. PMID: 31201848, PMCID: PMC6754783, DOI: 10.1016/j.bbi.2019.06.017.Peer-Reviewed Original ResearchConceptsN-methyl-D-aspartate (NMDA) glutamate receptorsFirst-episode patientsNMDAR antibodiesAntibody levelsHealthy controlsSerum anti-NMDAR antibodyTotal scoreAnti-NMDAR antibodiesNMDAR antibody levelsNMDAR-antibody encephalitisElevated levelsReceptor antibody levelsSerum antibody levelsTreatment of schizophreniaPathogenesis of schizophreniaNegative Syndrome ScaleSymptoms of psychosisEnzyme-linked immunosorbentEtiology of schizophreniaMCCB total scoreAntibody encephalitisPatient groupNMDAR dysfunctionSchizophrenia (MATRICS) Consensus Cognitive BatteryGlutamate receptors
2016
Association of catechol-O-methyltransferase Val108/158 Met genetic polymorphism with schizophrenia, P50 sensory gating, and negative symptoms in a Chinese population
Mao Q, Tan Y, Luo X, Tian L, Wang Z, Tan S, Chen S, Yang G, An H, Yang F, Zhang X. Association of catechol-O-methyltransferase Val108/158 Met genetic polymorphism with schizophrenia, P50 sensory gating, and negative symptoms in a Chinese population. Psychiatry Research 2016, 242: 271-276. PMID: 27315458, DOI: 10.1016/j.psychres.2016.04.029.Peer-Reviewed Original ResearchConceptsPCR-restriction fragment length polymorphismSchizophrenic patientsP50 deficitsNegative symptomsChinese populationNegative Syndrome ScaleRisk of schizophreniaSymptoms of schizophreniaP50 sensory gatingVal allele carriersHan Chinese populationRole of COMTCerebral cortexClinical symptomatologyHealthy controlsNegative subscoreAllele carriersMetS individualsMet/Met individualsControl groupSensory gatingSyndrome ScaleGenotype distributionP50 gatingSchizophrenic subjects
2014
Smoking and BDNF Val66Met polymorphism in male schizophrenia: A case-control study
Zhang XY, Chen DC, Tan YL, Luo X, Zuo L, Lv MH, Shah NN, Zunta-Soares GB, Soares JC. Smoking and BDNF Val66Met polymorphism in male schizophrenia: A case-control study. Journal Of Psychiatric Research 2014, 60: 49-55. PMID: 25455509, DOI: 10.1016/j.jpsychires.2014.09.023.Peer-Reviewed Original ResearchConceptsVal/Val genotypeBDNF Val66Met polymorphismHealthy controlsNicotine dependenceVal66Met polymorphismVal genotypeSchizophrenia patientsChronic male schizophrenia patientsMet alleleBDNF Val66Met gene polymorphismBDNF Val66Met genotypePANSS negative symptomsHigher FTND scoresCase-control studyMale schizophrenia patientsNegative Syndrome ScaleChinese Han populationCase-control designVal66Met genotypeMore hospitalizationsPatient groupSmoking indexMale schizophreniaFagerstrom TestHigh HSI scores
2013
Cognitive Function, Plasma MnSOD Activity, and MnSOD Ala-9Val Polymorphism in Patients With Schizophrenia and Normal Controls
Zhang XY, Chen D, Xiu MH, Yang FD, Tan Y, Luo X, Zuo L, Kosten TA, Kosten TR. Cognitive Function, Plasma MnSOD Activity, and MnSOD Ala-9Val Polymorphism in Patients With Schizophrenia and Normal Controls. Schizophrenia Bulletin 2013, 40: 592-601. PMID: 23588476, PMCID: PMC3984504, DOI: 10.1093/schbul/sbt045.Peer-Reviewed Original ResearchConceptsAla-9Val polymorphismNormal controlsCognitive impairmentMnSOD activityAla allele carriersChronic schizophrenic patientsMitochondrial enzyme manganese superoxide dismutaseNegative Syndrome ScaleEnzyme manganese superoxide dismutaseHealthy controlsManganese superoxide dismutaseAllele carriersExcessive reactive oxygen speciesSchizophrenic patientsSchizophrenic inpatientsSyndrome ScaleCognitive deficitsNeuropsychological StatusCognitive functionPatients' psychopathologyRepeatable BatteryPatientsSchizophreniaTotal scoreReactive oxygen species
2012
Association of functional dopamine-beta-hydroxylase (DBH) 19bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers
Zhang XY, Chen D, Xiu MH, Hui L, Liu H, Luo X, Zuo L, Zhang H, Kosten TA, Kosten TR. Association of functional dopamine-beta-hydroxylase (DBH) 19bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers. Schizophrenia Research 2012, 141: 48-53. PMID: 22871345, DOI: 10.1016/j.schres.2012.07.011.Peer-Reviewed Original ResearchConceptsSchizophrenic smokersHealthy controlsNicotine dependenceDrug rewardLower FTND scoresIns/ins genotypeDopamine beta‐hydroxylase polymorphismInsertion/deletion polymorphismCase-control designClinician-administered questionnairesSmoking severityMale schizophreniaFagerstrom TestFTND scoreSmoking behaviorModel groupNicotine useSchizophrenia patientsSmokersDel genotypeMale controlsPatientsDel polymorphismFunctional polymorphismsIns genotype